A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Diane A. J. van der Biessen 1 · Jourik A. Gietema 2 · Maja J. A. de Jonge 1 · Ingrid M. E. Desar 3 · Martha W. den Hollander 2 · Matthew Dudley 4 · Martin Dunbar 4 · Robert Hetman 4 · Camille Serpenti 5 · Hao Xiong 4 · Rajendar K. Mittapalli 4 · Kirsten M. Timms 6 · Peter Ansell 4 · Christine K. Ratajczak 4 · Stacie Peacock Shepherd 4 · Carla M. L. van Herpen 3

Received: 20 November 2017 / Accepted: 12 December 2017 / Published online: 8 January 2018
© The Author(s) 2018. This article is an open access publication

Summary

Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients received ABT-767 monotherapy orally until disease progression or unacceptable toxicity. Dose was escalated from 20 mg once daily to 500 mg twice daily (BID). Dose-limiting toxicities, recommended phase 2 dose (RP2D), food effect, objective response rate, and biomarkers predicting response were determined. Results Ninety-three patients were treated with ABT-767; 80 had a primary diagnosis of ovarian cancer. ABT-767 demonstrated dose-proportional PK up to 500 mg BID and half-life of ~2 h. Food had no effect on ABT-767 bioavailability. Most common grade 3/4 treatment-related adverse events were nausea, fatigue, decreased appetite, and anemia. Anemia showed dose-dependent increase. RP2D was 400 mg BID. Objective response rate by RECIST 1.1 was 21% (17/80) in all evaluable patients and 20% (14/71) in evaluable patients with ovarian cancer. Response rate by RECIST 1.1 and/or CA-125 was 30% (24/80) in patients with ovarian cancer. Mutations in BRCA1 or BRCA2, homologous recombination deficiency (HRD), and platinum sensitivity were associated with tumor response. Median progression-free survival was longer for HRD positive (6.7 months) versus HRD negative patients (1.8 months) with ovarian cancer. Conclusions ABT-767 had an acceptable safety profile up to the established RP2D of 400 mg BID and dose-proportional PK. Patients with BRCA1 or BRCA2 mutation, HRD positivity, and platinum sensitivity were more sensitive to ABT-767.

Keywords PARP inhibitor · BRCA · Solid tumor · Ovarian cancer · Homologous recombination deficiency

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10637-017-0551-z) contains supplementary material, which is available to authorized users.

Introduction

Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are nuclear enzymes that recognize DNA damage and facilitate DNA repair [1, 2]. Malignancies with deficiencies in homologous recombination, such as those with breast cancer gene (BRCA) mutations, are more dependent on PARP for DNA repair than normal cells and are therefore more sensitive to PARP inhibition [3]. Accordingly, monotherapy PARP inhibitors have shown antitumor activity in BRCA mutated tumors [4–8].

In patients with breast cancer, mutations in the BRCA1/2 genes account for 5% of all breast cancers and 15–20% of all hereditary breast cancers [9, 10]. BRCA1/2 mutations also account for an increased risk of early-onset prostate cancer, gastric and pancreatic cancer [11]. Approximately 20% of
Materials and methods

Patients

Patients were screened at three sites in the Netherlands. Eligible patients were 18 years or older with histologically or cytologically confirmed malignancy that was metastatic or unresectable, and for which standard curative measures did not exist or were no longer effective. All patients had either a documented deleterious BRCA1 or BRCA2 mutation or high-grade serous ovarian, fallopian tube, or peritoneal cancer, Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, and adequate hematologic, renal and hepatic function. In the Expanded Safety Cohort #1, all patients had a documented deleterious BRCA1/2 mutation, a lesion accessible for biopsy, and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. In the Expanded Safety Cohort #2, all patients had a known positive or negative status for deleterious BRCA1/2 mutation. Patients in the Expanded Safety Cohort #2 with ovarian cancer could have non-measurable disease in case of an elevated serum cancer antigen-125 (CA-125) level by Gynecologic Cancer Intergroup (GCIG) criteria.

Patients were not eligible if they received anti-cancer therapy within 28 days or 5 half-lives (whichever was shorter) of the first dose of study drug, if they had central nervous system metastases, unresolved clinically significant toxicities from their prior anti-cancer therapy, clinically significant uncontrolled condition(s), or if they were pregnant or breastfeeding. In the Expanded Safety Cohorts, patients were not eligible if they had received a prior PARP inhibitor.

Study design and treatment

This was a phase 1, open-label, non-randomized, dose-escalation study (NCT01339650) of ABT-767 to determine the dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D). ABT-767 was administered orally to patients on days 1–28 of 28-day cycles. Patients continued to receive ABT-767 until they experienced progression per RECIST 1.1 or unacceptable toxicity. Intra-patient dose escalation was allowed in patients who experienced clinical worsening or who had stable disease and who may benefit from dose escalation in the opinion of the investigator.

Patient cohorts were administered ascending doses of ABT-767. The initial dose was 20 mg once daily (QD). Doses for subsequent cohorts were administered twice daily (BID) and were doubled until a grade 2 toxicity occurred during cycle 1; following a grade 2 toxicity, dose escalations were restricted to between 25% and 75% of the previous dose. The decision to escalate the dose was based on observed DLTs, other adverse events, and PK data. A modified 3 + 3 design was used to determine MTD and RP2D. Each dose level included at least 3 evaluable patients but could enroll up to 9 patients. If one patient within any dose level experienced a DLT, the cohort was expanded to at least 6 patients. The dose could be escalated if >67% of patients in a cohort did not experience a DLT in Cycle 1. MTD was defined as the highest dose level at which less than 2 out of 6 patients or <33% of patients experienced a DLT. The RP2D was defined by observed DLTs and determination of MTD.

After determination of RP2D, additional patients were enrolled to two Expanded Safety Cohorts to further evaluate the safety, tolerability, and PK of ABT-767 at the RP2D. Food effect was assessed in the Expanded Safety Cohort enrollment patients with BRCA1/2 germline mutation and advanced solid tumors only.

Safety and tolerability

Safety was evaluated throughout the study through assessment of treatment-emergent adverse events (TEAEs) and laboratory tests. TEAEs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Treatment-related TEAEs were those considered possibly or probably related to ABT-767.

The following TEAEs were considered DLTs if occurring during the first cycle of dosing and attributed to ABT-767: grade 4 absolute neutrophil count (ANC), grade 3 ANC lasting more than 7 days, or ≥ grade 3 ANC with fever, ≥ grade 3 thrombocytopenia; ≥ grade 3 decreased hemoglobin; non-hematologic toxicities of CTCAE ≥ grade 3 that have increased at least grade 2 levels from baseline (except nausea, vomiting, diarrhea, and tumor pain that have not received optimal treatment); creatinine increases to grade 3 that are not corrected to grade 1 or baseline within 24 h by IV fluids; ≥ grade 3 metabolic toxicities not corrected to ≤ grade 2 within 24 h or any
symptomatic grade 4 metabolic toxicity; or grade 2 non-hematologic toxicities representing ≥2 grade increase from baseline requiring dose modification or delay of >1 week.

**Pharmacokinetics**

ABT-767 was administered as a single dose under fasting conditions on day −4 (for patients being evaluated for food effect) and as either QD or BID under non-fasting conditions on study days 1 through 28. ABT-767 PK samples were collected at 0, 0.5, 1, 1.5, 2, 4, 6, 8, 10 and 24 h post-dose on Cycle 1 Days −4, 1, and 8. Urine sample collections started immediately after the ABT-767 morning dose on Cycle 1 Day 7 and ended immediately prior to the morning dose on Cycle 1 Day 8. Maximum observed plasma concentration (Cmax), the time to Cmax (peak time, Tmax), and the area under the concentration curve (AUCt) were determined using non-compartmental methods.

**Exploratory efficacy**

Objective response rate (ORR: confirmed complete response [CR] plus partial response [PR]) was based on RECIST version 1.1, and was evaluated in patients with measurable disease at baseline. Tumor marker CA-125 response was measured by GCIG criteria [15] in patients with ovarian cancer, and was evaluated in patients with a pre-treatment sample within 2 weeks of starting treatment that was at least twice the upper limit of normal. Time of progression-free survival was defined as the number of days from first dose of study drug to disease progression or death if disease progression was not reached. Six-month progression-free survival (PFS) rate was calculated.

**Biomarker analysis**

BRCA status was collected at screening if known. A known BRCA status was required for patients in the expansion cohorts. Tumor BRCA1/2 mutation status and homologous recombination deficiency (HRD) score were analyzed using a next generation sequencing assay (Myriad) in patients providing tissue samples in a central lab [16]. Tumors were considered HRD positive if they had an HRD score ≥42 and/or a BRCA1/2 mutation, as previously described [17].

**Statistical analysis**

All patients who received at least one dose of ABT-767 were included in the safety, PK, and efficacy analyses. For all statistical analyses, unless otherwise stated, statistical significance was determined using a two-sided p value ≤0.05. The Kaplan-Meier method was used to estimate PFS. Data were analyzed both by specific ABT-767 dose cohort and in some cases by pooling multiple cohorts.

Dose, BRCA mutation status, platinum sensitivity, baseline CA-125 level (if relevant), and age were examined as potential predictive variables for efficacy (PFS and best tumor response) and safety (anemia). A logistic regression analysis was performed to characterize the dose-response relationship between the ABT-767 dose and best tumor response (CR or PR).

**Results**

**Patient characteristics and treatment exposure**

A total of 93 patients were enrolled and treated in the dose escalation (n = 63) or expanded safety (n = 30) cohorts. Patient demographics and baseline clinical characteristics are summarized in Table 1. The majority of patients (86%) had a primary diagnosis of ovarian cancer, and 45% (42/93 patients) had known germline BRCA1/2 mutations.

The median duration of ABT-767 treatment among all 93 patients was 3.8 months (range 0.03–31.1) as of data cutoff on March 29, 2016. The median duration for patients in the dose escalation was 3.8 months (range 0.03–20.6), and the median duration for patients in the expanded safety cohorts was 4.0 months (0.5–31.1).

**Dose-limiting toxicities and recommended dose**

DLTs occurred in three patients during the DLT evaluation period; angina pectoris in one patient at 20 mg BID, and grade 3 anemia in two patients at 400 mg and 500 mg BID. The RP2D was determined to be 400 mg BID. The 500 mg BID dose was considered intolerable due to grade 3 anemia and fatigue/general malaise.

**Safety**

Eighty-seven patients (93.5%) experienced at least one treatment-related adverse event, and 40 patients (43%) experienced at least one grade 3 or 4 treatment-related TEAE. Grade 3 or 4 treatment-related adverse events occurring in more than one patient overall were anemia (31.2%), fatigue (5.4%), decreased appetite (2.2%), neutropenia (2.2%), and thrombocytopenia (2.2%) (Table 2). A dose-dependent increase in all-grade anemia was observed with ABT-767 from 20 mg BID (16.7%) to 500 mg BID (66.7%). Mean hemoglobin levels for all patients from screening visit to Cycle 3 Day 1 are shown in Supplemental Fig. 1.

Two patients had treatment-related TEAEs that led to discontinuation (thrombocytopenia in one patient at 20 mg BID, and decreased platelet count and anemia in one patient at 400 mg BID).
BID). Twenty-nine patients (31.2%) experienced at least one TEAE that led to ABT-767 dose reduction; dose reduction was due to anemia in 20 of these patients. Thirty-five patients had a treatment-related TEAE that led to ABT-767 interruption. Treatment-related TEAEs leading to dose reduction and interruption were generally more frequent with increasing dose.

Six patients (6.5%) experienced at least one treatment-related serious TEAE (dizziness and angina pectoris in one patient; abdominal pain, dehydration, and nausea in one patient; abdominal pain, nausea, malaise, and vomiting in one patient; and malaise, macular hole, and lung infection in one patient each).

### Pharmacokinetics

ABT-767 exposure increased approximately dose-proportionally from 20 mg to 500 mg (Fig. 1). The median

| Table 1 Patient demographic and baseline clinical characteristics | Dose escalation (N = 63) | Expanded safety (N = 30) | Total (N = 93) |
|---------------------------------------------------------------|-------------------------|-------------------------|---------------|
| **Sex, n (%)**                                                |                         |                         |               |
| Female                                                        | 62 (98)                 | 30 (100)                | 92 (99)       |
| **Age, years**                                               |                         |                         |               |
| Mean (SD)                                                     | 57 (11)                 | 59 (10)                 | 58 (11)       |
| Median (range)                                                | 57 (27–80)              | 60 (33–73)              | 58 (27–80)    |
| **Race, n (%)**                                              |                         |                         |               |
| White                                                         | 63 (100)                | 28 (93)                 | 91 (98)       |
| Asian                                                         | 0                       | 2 (7)                   | 2 (2)         |
| **Primary diagnosis**, n (%)                                  |                         |                         |               |
| Ovarian, fallopian tube, or primary peritoneal                | 54 (86)                 | 26 (87)                 | 80 (86)       |
| Fallopian tube, n                                             | 3                       | 0                       | 3             |
| Primary peritoneal, n                                         | 2                       | 1                       | 3             |
| Breast                                                        | 7 (11)                  | 3 (10)                  | 10 (11)       |
| Pancreatic                                                    | 0                       | 1 (3)                   | 1 (1)         |
| Prostate                                                      | 1 (2)                   | 0                       | 1 (1)         |
| Peritoneal mesothelioma                                       | 1 (2)                   | 0                       | 1 (1)         |
| **Prior therapies, n (%)**                                   |                         |                         |               |
| Number of prior therapies                                    |                         |                         |               |
| 1                                                             | 9 (14)                  | 4 (13)                  | 13 (14)       |
| 2                                                             | 17 (27)                 | 11 (37)                 | 28 (30)       |
| 3                                                             | 11 (17)                 | 5 (17)                  | 16 (17)       |
| 4                                                             | 15 (24)                 | 8 (27)                  | 23 (25)       |
| ≥ 5                                                           | 11 (17)                 | 2 (7)                   | 13 (14)       |
| ≥ 1 PARP inhibitor-containing therapy                         | 5 (8)                   | 0                       | 5 (5)         |
| ≥ 1 platinum-containing therapy                               | 59 (94)                 | 27 (90)                 | 86 (93)       |
| Platinum-free interval < 6 months                             | 32 (51)                 | 10 (33)                 | 42 (45)       |
| Platinum-free interval 6–12 months                            | 20 (32)                 | 11 (37)                 | 31 (33)       |
| Platinum-free interval > 12 months                            | 6 (10)                  | 4 (13)                  | 10 (11)       |
| **BRCA status, n (%)**                                       |                         |                         |               |
| Germline BRCA1/BRCA2 mutation positive                        | 26 (41)                 | 16 (53)                 | 42 (45)       |
| Germline BRCA1/BRCA2 mutation negative                        | 11 (18)                 | 13 (43)                 | 24 (26)       |
| Germline BRCA1/BRCA2 mutation status unknown                  | 26 (41)                 | 1 (3)                   | 27 (29)       |

**Abbreviations:** PARP poly(ADP-ribose) polymerase; SD standard deviation

a 21 patients had a history of other malignancies including breast, colorectal, melanoma, renal, and basal or squamous cell skin cancer

b Platinum-free interval was defined as the time in months between last dose of platinum-based therapy and start of the next line of therapy. Platinum-free interval data are missing for 3 patients with prior platinum (1 in Dose Escalation Cohort, and 2 in Expanded Safety Cohort). Patients with a platinum-free interval of <6, 6–12, and >12 months were considered platinum resistant, partially platinum sensitive, and platinum sensitive, respectively

c BRCA1/2 mutation as reported by site at screening
T<sub>max</sub> values ranged from 1.5 to 2.0 h under non-fasting condition, and the harmonic mean half-life was approximately 2 h across different cohorts (Supplemental Table 1). On average, 10% of ABT-767 dose was recovered as the parent drug in urine, and renal clearance appeared to be independent of dose, which suggests that renal clearance plays an important role in ABT-767 elimination. The effect of food on the oral bioavailability of ABT-767 was evaluated up to 400 mg ABT-767 dose, and no significant food effect was seen on C<sub>max</sub> or AUC of ABT-767.

**Efficacy**

Among all patients, the objective response rate (CR + PR) by RECIST 1.1 criteria was 21% ([17/80], 95% CI: 13–32%). Among patients with ovarian cancer, the objective response rate by RECIST 1.1 criteria was 20% ([14/71], 95% CI: 11–31%), by GCIC (CA-125) criteria 35% ([23/65], 95% CI: 24–48%), and by using RECIST 1.1 and/or CA-125 criteria 30% ([24/80], 95% CI: 20–41%). Duration of therapy and best tumor response (RECIST 1.1) for individual patients are shown in Fig. 2.

The best percentage change from baseline in tumor size by ABT-767 dose is shown in Fig. 3. A ≥30% reduction from baseline in tumor size was seen in 19 of 76 patients who had a post-baseline measurement.

The 6-month PFS rate was 33% (95% CI: 23–42%) for all patients, and 32% (95% CI: 22–42%) for patients with ovarian cancer. The median PFS was 3.8 months (95% CI: 2.8–5.2 months) for all patients, 3.7 months (95% CI: 2.7–4.7 months) for patients with ovarian cancer, and 5.6 months (95% CI: 1.8–7.7 months) for patients with other types of primary cancer.

**Biomarker analysis**

Somatic BRCA mutation status and HRD status were determined for 60 patients with ovarian cancer for whom tissue was submitted. Thirty-four patients had ovarian tumors that were HRD positive; of these, 26 had deleterious BRCA mutations. Of the 34 HRD positive patients, 16 (47%) were responders (7 PR, 9 CR) per RECIST 1.1 and/or CA-125 criteria; all 16 responders had prior platinum and 2 were platinum resistant. Among the HRD positive patients who had a deleterious somatic BRCA mutation, 14/26 (54%) were responders (7 PR, 7 CR) per RECIST 1.1 and/or CA-125 criteria (Table 3). Among the 8 patients who were HRD positive but had no deleterious BRCA mutation, 2 were responders by RECIST 1.1 and/or CA-125 criteria. Both of these patients were partially platinum sensitive, received ABT-767 at 400 mg BID and had a CR. Among patients determined to be HRD negative, there were no responders per RECIST 1.1 or CA-125 criteria. Among HRD positive patients with ovarian cancer,
responses were generally more frequent in patients with fewer prior therapies (Supplemental Table 2).

PFS was significantly longer in HRD positive patients with ovarian cancer (median PFS 6.7 months; n = 34) compared with HRD negative patients (median PFS 1.8 months; n = 26) (Log rank p < 0.0001) (Supplemental Fig. 2).

**Predictors of response**

In univariate analysis, platinum sensitivity (compared to platinum resistant population) was a significant covariate (p < 0.01) affecting best tumor response by RECIST, whereas ABT-767 dose and BRCA mutational status (germline compared to non-germline) showed a trend toward significance (p < 0.1) (Supplemental Fig. 3). In multivariate analysis, platinum sensitivity was a statistically significant covariate affecting the best tumor response by RECIST (p < 0.01). Both univariate and multivariate analyses revealed that PFS is significantly affected by BRCA mutational status (germline compared to non-germline; p < 0.05) and by platinum sensitivity (platinum sensitive compared to platinum resistant population; p < 0.05) (Supplemental Fig. 3 B-C).

**Discussion**

This phase 1 study evaluated ABT-767 in patients with ovarian cancer or BRCA mutations. ABT-767 had an acceptable safety profile up to the established RP2D of 400 mg BID. Anemia was the most common grade 3/4
BRCA1/2 restricted to HRD positive patients. Responses were generally served RECIST and/or CA-125 responses were generally significantly prolonged in patients who were HRD positive, and observing HRD positive patients with ovarian cancer. PFS was significantly affected by the inclusion of archived tissue that may have been from the sample size of HRD positive BRCA1/2 mutation (N = 26) was 9 (27%) 7 (27%) 12 (46%) (N = 8) was 2 (25%) 26 (100%) and HRD undetermined (N = 7) was 1 (14%) 0 6 (86%).

Abbreviations: HRD homologous recombination deficiency

TEAE: onset of anemia was monitorable and was generally manageable with standard supportive care and dose reduction. Anemia has been frequently reported with other PARP inhibitors [4, 7, 8]. The half-life of ABT-767 was approximately 2 h and renal clearance was a significant pathway for ABT-767 elimination. The exposure to ABT-767 increased approximately dose-proportionally from 20 mg to 500 mg. Food had no significant effect on ABT-767 oral bioavailability up to 400 mg dose. The data suggest that ABT-767 has single-agent activity in patients with tumors with BRCA mutations or high-grade serous ovarian cancer, with tumor responses of 21% (17/80 patients) in all patients per RECIST 1.1 criteria, and 30% (24/80 patients) in patients with ovarian cancer per CA-125 and/or RECIST 1.1 criteria.

Biomarker analyses indicate ABT-767 sensitivity among HRD positive patients with ovarian cancer. PFS was significantly prolonged in patients who were HRD positive, and observed RECIST and/or CA-125 responses were generally restricted to HRD positive patients. Responses were generally more common among HRD positive patients who had a somatic BRCA1/2 mutation compared to those who did not; however, the sample size of HRD positive BRCA1/2 wild-type patients was small at only 8 patients. Patient selection with a functional HRD test [16] or RAD51 assay [18] may be useful for identifying patients likely to respond. The biomarker analyses are limited by the collection of tissue in a subset of patients, and the inclusion of archived tissue that may have been from the time of diagnosis in patients who received multiple prior lines of therapy. It was observed that patients were generally less likely to respond with increasing number of prior lines of therapy. Mechanisms of resistance and possible BRCA1/2 reversion mutations were not evaluated in this study. Univariate and multivariate analyses showed that PFS is significantly affected by BRCA mutation and platinum sensitivity, further delineating patient populations that may benefit from therapy.

In this phase 1 study of ABT-767, responses were observed in a refractory, heterogeneous patient population. Patients with BRCA mutations, HRD positivity, and platinum sensitivity were more sensitive to treatment, supporting that these populations are suitable candidates for PARP inhibitor therapy.

Acknowledgements AbbVie and the authors thank the patients who participated in this clinical trial and all study investigators for their contributions. Medical writing assistance was provided by Ana Mrejeru, Ph.D. (AbbVie) and editorial assistance by Mary L. Smith, Ph.D. (TRM Oncology).

Funding AbbVie Inc. provided financial support for this study and participated in the design, study conduct, analysis, and interpretation of the data, as well as the writing, review, and approval of this manuscript.

Compliance with ethical standards This study was conducted in accordance with the protocol, International Conference on Harmonization Good Clinical Practice guidelines, applicable regulations and guidelines governing clinical study conduct, and ethical principles that have their origin in the Declaration of Helsinki. The study has been approved by the local ethics committees.

Conflict of interest DAJvdB, JAG, MJAdJ, IMED, MWDH, and CMLvH have no conflicts of interest to declare.

Conflict of interest DAJvdB, JAG, MJAdJ, IMED, MWDH, and CMLvH have no conflicts of interest to declare.

KMT is a Myriad employee and may own Myriad stock. M Dudley, M Dunbar, RH, CS, HK, RMK, CRK, and PA are AbbVie employees and may own AbbVie stock. SPS was an AbbVie employee at time of study and may own AbbVie stock.

Informed consent Patients provided written informed consent before participation in the trial.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Table 3 Tumor response by RECIST 1.1 and/or CA-125 by HRD and somatic BRCA1/2 mutation status in patients with ovarian cancer

| BRCA1/2 mutation | Complete Response | Partial Response | Non-Responder |
|------------------|------------------|-----------------|--------------|
| (N = 34)         | 9 (26%)          | 7 (21%)         | 18 (53%)     |
| (N = 26)         | 7 (27%)          | 7 (27%)         | 12 (46%)     |
| (N = 8)          | 2 (25%)          | 0               | 6 (75%)      |
| HRD negative (N = 26) | 0               | 0               | 26 (100%)    |
| HRD undetermined (N = 7) | 1 (14%)    | 0               | 6 (86%)      |

References

1. Chiarugi A (2002) Poly(ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisited. Trends Pharmacol Sci 23(3):122–129. https://doi.org/10.1016/S0140-6736(00)01902-7
2. Virag L, Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54(3):375–429
3. Lee JM, Ledermann JA, Kohn EC (2014) PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 25(1):32–40. https://doi.org/10.1093/annonc/mdt384
4. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S et al (2013) The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol 14(9):882–892. https://doi.org/10.1016/S1470-2045(13)70240-7
5. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737):235–244. https://doi.org/10.1016/S0140-6736(10)60892-6
6. Audeh MW, Carmichael J, Pensio RT, Friedlander M, Powell B, Bell-McGuinn KM et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet
7. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmna J et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33(3):244–250. https://doi.org/10.1200/JCO.2014.56.2728

8. Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS et al (2015) A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG oncology/gynecologic oncology group study. Gynecol Oncol 137(3):386–391. https://doi.org/10.1016/j.ygyno.2015.03.042

9. Balmna J, Diez O, Rubio IT, Cardoso F, Group EGW. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22 Suppl 6:vi31–vi34 https://doi.org/10.1093/annonc/mdr373.

10. Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329–1333. https://doi.org/10.1200/JCO.2006.09.1066

11. Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A (2006) BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers. Crit Rev Oncol Hematol 57(1):1–23. https://doi.org/10.1016/j.critrevonc.2005.05.003

12. Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615. https://doi.org/10.1038/nature10166

13. Matsumoto K, Onda T, Yaegashi N (2015) Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives. Jpn J Clin Oncol 45(5):408–410. https://doi.org/10.1093/jjco/hvy014

14. de Jonge MJA, van Herpen C, Gietema JA, Shepherd S, Koornstra R, Jager A, et al. A study of ABT-767 in advanced solid tumors with BRCA 1 and BRCA 2 mutations and high grade serous ovarian, fallopian tube, or primary peritoneal cancer. Ann Oncol 2014;25(Suppl 4):iv150 doi: https://doi.org/10.1093/annonc/mdu331.12.

15. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T et al (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer 21(2):419–423. https://doi.org/10.1097/IGC.0b013e3182070f17

16. Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B et al (2014) Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes. Breast Cancer Res 16(6):475. https://doi.org/10.1186/s13058-014-0475-x.

17. Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC et al (2016) Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 22(15):3764–3773. https://doi.org/10.1158/1078-0432.CCR-15-2477

18. Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S et al (2010) Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 16(8):2344–2351. https://doi.org/10.1158/1078-0432.CCR-09-2758